Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ analysis
Carcinoma, Renal Cell
/ chemistry
Databases, Factual
Female
Fumarate Hydratase
/ analysis
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Kidney Neoplasms
/ chemistry
Male
Membrane Proteins
/ genetics
Middle Aged
Neoplasm Grading
Neoplasm Staging
Retrospective Studies
Succinate Dehydrogenase
/ analysis
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
pubmed:
27
11
2020
medline:
11
5
2021
entrez:
26
11
2020
Statut:
ppublish
Résumé
Our recent study of early-onset unclassified eosinophilic renal cell carcinoma (RCC) demonstrated that two third of cases could be reclassified by performing a limited number of immunohistochemistry stains. Following the same approach, we aimed to investigate what proportion of adult unclassified RCC could be reclassified. We identified 79 cases. The mean age at presentation was 58 years (range, 29 to 84 y). Tumors were grouped based on their predominant morphologic features as oncocytic (n=23); papillary (n=22); clear cell (n=22); mucinous tubular and spindle cell (MTSC; n=5); rhabdoid (n=4); or lacking a dominant pattern (n=3). By reviewing the morphologic features and performing ancillary studies, we were able to reclassify 10 cases (13%). Four cases were positive for CK20 and showed morphologic features consistent with eosinophilic solid and cystic RCC. Four cases were reclassified as MTSC based on VSTM2A expression by RNA in situ hybridization. One case was negative for SDHB and reclassified as succinate dehydrogenase-deficient RCC. None of the cases showed loss of expression of fumarate hydratase. One case was diffusely positive for CK7 and negative for CD117 and reclassified as a low-grade oncocytic tumor. Four cases were positive for both cathepsin-K and TFE3 by immunohistochemistry, although fluorescence in situ hybridization failed to identify rearrangement in either TFE3 or TFEB genes. Of the tumors that remained unclassified, those with oncocytic features were less likely to be a high grade (odds ratio [OR]=0.22, P=0.013) or advanced stage (OR=0.19, P=0.039) and were more common in women (OR=3.4, P=0.05) compared with those without oncocytic features. Tumors with rhabdoid morphology were associated with advanced stage (relative risk=3.6, P=0.009), while tumors with clear cell or papillary features had a wide range of grades and stages at presentation. In summary, the most frequent reclassified entity is eosinophilic solid and cystic RCC. Investigation of expression of succinate dehydrogenase or fumarate hydratase in individuals older than 35 years with unclassifiable tumors is low yield in the absence of specific morphologic features. A subset of MTSC without well-developed morphologic features can be reclassified by using RNA-ISH for VSTM2A. Recognition of more-recently described RCC subtypes allows for their distinction from the unclassified subtype and improves the prognostic information provided.
Identifiants
pubmed: 33239504
pii: 00000478-202104000-00002
doi: 10.1097/PAS.0000000000001629
doi:
Substances chimiques
Biomarkers, Tumor
0
Membrane Proteins
0
VSTM2A protein, human
0
Succinate Dehydrogenase
EC 1.3.99.1
Fumarate Hydratase
EC 4.2.1.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
450-462Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: Supported in part by the Joseph C. Eggleston Award in Surgical Pathology to R.K. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.
Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105.
Cairns P. Renal cell carcinoma. Cancer Biomark. 2010;9:461–473.
Lopez-Beltran A, Kirkali Z, Montironi R, et al. Unclassified renal cell carcinoma: a report of 56 cases. BJU Int. 2012;110:786–793.
Perrino CM, Grignon DJ, Williamson SR, et al. Morphological spectrum of renal cell carcinoma, unclassified: an analysis of 136 cases. Histopathology. 2018;72:305–319.
Crispen PL, Tabidian MR, Allmer C, et al. Unclassified renal cell carcinoma: impact on survival following nephrectomy. Urology. 2010;76:580–586.
Hu ZY, Pang LJ, Qi Y, et al. Unclassified renal cell carcinoma: a clinicopathological, comparative genomic hybridization, and whole-genome exon sequencing study. Int J Clin Exp Pathol. 2014;7:3865–3875.
Karakiewicz PI, Hutterer GC, Trinh QD, et al. Unclassified renal cell carcinoma: an analysis of 85 cases. BJU Int. 2007;100:802–808.
Zisman A, Chao DH, Pantuck AJ, et al. Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype. J Urol. 2002;168:950–955.
Kim SH, Yang HK, Moon KC, et al. Localized non-conventional renal cell carcinoma: prediction of clinical outcome according to histology. Int J Urol. 2014;21:359–364.
Trpkov K, Hes O. New and emerging renal entities: a perspective post-WHO 2016 classification. Histopathology. 2019;74:31–59.
Li Y, Reuter VE, Matoso A, et al. Re-evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients. Histopathology. 2018;72:588–600.
Akgul M, Cheng L. Immunophenotypic and pathologic heterogeneity of unclassified renal cell carcinoma: a study of 300 cases. Hum Pathol. 2020;102:70–78.
Argani P, Zhong M, Reuter VE, et al. TFE3-fusion variant analysis defines specific clinicopathologic associations among Xp11 translocation cancers. Am J Surg Pathol. 2016;40:723–737.
Wang L, Zhang Y, Chen YB, et al. VSTM2A overexpression is a sensitive and specific biomarker for mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney. Am J Surg Pathol. 2018;42:1571–1584.
Argani P, Lal P, Hutchinson B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27:750–761.
Argani P, Reuter VE, Eble JN, et al. Biphasic hyalinizing psammomatous renal cell carcinoma (BHP RCC): a distinctive neoplasm associated with somatic NF2 mutations. Am J Surg Pathol. 2020;44:901–916.
Trpkov K, Hes O, Bonert M, et al. Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol. 2016;40:60–71.
Skala SL, Wang X, Zhang Y, et al. Next-generation RNA sequencing-based biomarker characterization of chromophobe renal cell carcinoma and related oncocytic neoplasms. Eur Urol. 2020;78:63–74.
Trpkov K, Williamson SR, Gao Y, et al. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology. 2019;75:174–184.
Sanz-Ortega J, Vocke C, Stratton P, et al. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome. Am J Surg Pathol. 2013;37:74–80.
Smith SC, Sirohi D, Ohe C, et al. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma. Histopathology. 2017;71:42–52.
Yakirevich E, Ali SM, Mega A, et al. A novel SDHA-deficient renal cell carcinoma revealed by comprehensive genomic profiling. Am J Surg Pathol. 2015;39:858–863.
Ozluk Y, Taheri D, Matoso A, et al. Renal carcinoma associated with a novel succinate dehydrogenase A mutation: a case report and review of literature of a rare subtype of renal carcinoma. Hum Pathol. 2015;46:1951–1955.
Gupta S, Swanson AA, Chen YB, et al. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC. Hum Pathol. 2019;91:114–122.
Bulimbasic S, Ljubanovic D, Sima R, et al. Aggressive high-grade mucinous tubular and spindle cell carcinoma. Hum Pathol. 2009;40:906–907.
Kuroda N, Hes O, Michal M, et al. Mucinous tubular and spindle cell carcinoma with Fuhrman nuclear grade 3: a histological, immunohistochemical, ultrastructural and FISH study. Histol Histopathol. 2008;23:1517–1523.
Kuroda N, Naroda T, Tamura M, et al. High-grade mucinous tubular and spindle cell carcinoma: comparative genomic hybridization study. Ann Diagn Pathol. 2011;15:472–475.
Sakatani T, Okumura Y, Kuroda N, et al. Mucinous tubular and spindle cell carcinoma with a high nuclear grade and micropapillary pattern: a case report. Mol Clin Oncol. 2017;7:976–980.
Argani P, Netto GJ, Parwani AV. Papillary renal cell carcinoma with low-grade spindle cell foci: a mimic of mucinous tubular and spindle cell carcinoma. Am J Surg Pathol. 2008;32:1353–1359.
Macher-Goeppinger S, Roth W, Wagener N, et al. Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol. 2012;25:308–315.
Argani P, Zhang L, Reuter VE, et al. RBM10-TFE3 renal cell carcinoma: a potential diagnostic pitfall due to cryptic intrachromosomal Xp11.2 inversion resulting in false-negative TFE3 FISH. Am J Surg Pathol. 2017;41:655–662.
Sharain RF, Gown AM, Greipp PT, et al. Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study. Hum Pathol. 2019;87:65–74.
Martignoni G, Gobbo S, Camparo P, et al. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod Pathol. 2011;24:1313–1319.
Martignoni G, Pea M, Gobbo S, et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol. 2009;22:1016–1022.
Argani P, Reuter VE, Zhang L, et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol. 2016;40:1484–1495.
Chen YB, Mirsadraei L, Jayakumaran G, et al. Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am J Surg Pathol. 2019;43:121–131.
Palsgrove DN, Li Y, Pratilas CA, et al. Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum. Am J Surg Pathol. 2018;42:1166–1181.